HRP20221378T1 - Spojevi i postupci za modulaciju smn2 - Google Patents

Spojevi i postupci za modulaciju smn2 Download PDF

Info

Publication number
HRP20221378T1
HRP20221378T1 HRP20221378TT HRP20221378T HRP20221378T1 HR P20221378 T1 HRP20221378 T1 HR P20221378T1 HR P20221378T T HRP20221378T T HR P20221378TT HR P20221378 T HRP20221378 T HR P20221378T HR P20221378 T1 HRP20221378 T1 HR P20221378T1
Authority
HR
Croatia
Prior art keywords
modified oligonucleotide
modified
group
nucleosides
sugar residue
Prior art date
Application number
HRP20221378TT
Other languages
English (en)
Inventor
Frank Rigo
Thazha P. Prakash
Punit P. Seth
Original Assignee
Ionis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60952211&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20221378(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ionis Pharmaceuticals, Inc. filed Critical Ionis Pharmaceuticals, Inc.
Publication of HRP20221378T1 publication Critical patent/HRP20221378T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Claims (18)

1. Oligomerni spoj, naznačen time, što sadrži modificirani oligonukleotid koji se sastoji od 14-25 povezanih nukleozida, pri čemu je modificirani oligonukleotid komplementaran s pre-mRNA SMN2; i pri čemu najmanje jedan nukleozid od modificiranog oligonukleotida sadrži ostatak šećera modificiran 2'-O-(N-alkil acetamid) skupinom.
2. Oligomerni spoj prema patentnom zahtjevu 1, naznačen time, što: a. svaki od 7 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid); b. svaki od 8 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid); c. svaki od 9 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid); d. svaki od 10 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid); e. svaki od 11 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid); f. svaki od 12 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid); g. svaki od 13 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid); h. svaki od 14 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid); i. svaki od 15 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid); j. svaki od 16 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid); k. svaki od 17 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid); l. svaki od 18 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid); m. svaki od 19 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid); n. svaki od 20 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid).
3. Oligomerni spoj prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, što: a. svaki od ostataka šećera modificiranog skupinom 2'-O-(N-alkil acetamid) jest ostatak šećera modificiran skupinom 2'-O-(N-metil acetamid); ili b. svaki ostatak šećera od svakog nukleozida od modificiranog oligonukleotida jest ostatak šećera modificiran skupinom 2'-O-(N-alkil acetamid); ili c. svaki ostatak šećera od svakog nukleozida od modificiranog oligonukleotida jest ostatak šećera modificiran skupinom 2'-O-(N-metil acetamid).
4. Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, što: a. modificirani oligonukleotid se sastoji od 16-23 povezanih nukleozida; ili b. modificirani oligonukleotid se sastoji od 18-20 povezanih nukleozida.
5. Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, što: a. modificirani oligonukleotid se sastoji od 16 nukleozida; b. modificirani oligonukleotid se sastoji od 17 nukleozida; c. modificirani oligonukleotid se sastoji od 18 nukleozida; d. modificirani oligonukleotid se sastoji od 19 nukleozida; ili e. modificirani oligonukleotid se sastoji od 20 nukleozida.
6. Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, što se svaki međunukleozidni veznik od modificiranog oligonukleotida bira između fosforotioatnog međunukleozidnog veznika i fosfodiesterskog međunukleozidnog veznika, pri čemu opcionalno: a. modificirani oligonukleotid sadrži 5 fosfodiesterskih međunukleozidnih veznika; b. modificirani oligonukleotid sadrži 6 fosfodiesterskih međunukleozidnih veznika; ili c. modificirani oligonukleotid sadrži najmanje 6 fosfodiesterskih međunukleozidnih veznika.
7. Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, što modificirani oligonukleotid sadrži najmanje jednu modificiranu nukleobazu, opcionalno pritom modificirani oligonukleotid sadrži najmanje jedan 5-metil citozin.
8. Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, što: a. modificirani oligonukleotid je najmanje 70% komplementaran s pre-mRNA SMN2; b. modificirani oligonukleotid je najmanje 75% komplementaran s pre-mRNA SMN2; c. modificirani oligonukleotid je najmanje 80% komplementaran s pre-mRNA SMN2; d. modificirani oligonukleotid je najmanje 85% komplementaran s pre-mRNA SMN2; e. modificirani oligonukleotid je najmanje 90% komplementaran s pre-mRNA SMN2; f. modificirani oligonukleotid je najmanje 95% komplementaran s pre-mRNA SMN2; ili g. modificirani oligonukleotid je najmanje 100% komplementaran s pre-mRNA SMN2.
9. Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, što oligomerni spoj sadrži skupinu konjugata, pri čemu opcionalno skupina konjugata sadrži lipidnu ili lipofilnu skupinu, opcionalno pritom: a. lipidna ili lipofilna skupina se bira između kolesterola, C10-C26 zasićene masne kiseline, C10-C26 nezasićene masne kiseline, C10-C26 alkila, triglicerida, tokoferola, ili holne kiseline; b. lipidna ili lipofilna skupina je zasićeni ugljikovodični lanac ili nezasićeni ugljikovodični lanac; c. lipidna ili lipofilna skupina jest C16 alkil; ili d. lipidna ili lipofilna skupina jest zasićeni C16.
10. Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, što je modificirani oligonukleotid komplementaran s ISS-N1 od pre-mRNA SMN2.
11. Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, što nukleobazni slijed od modificiranog oligonukleotida sadrži slijed odabran od SEQ ID NO: 1, 2 ili 3, tako da se pritom nukleobazni slijed od modificiranog oligonukleotida sastoji od SEQ ID NO: 3.
12. Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, što oligomerni spoj je jednolančani.
13. Modificirani oligonukleotid, naznačen time, što se sastoji od 18 povezanih nukleozida i ima nukleobazni slijed SEQ ID NO: 3, pri čemu svaki nukleozid od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-metil acetamid), i time, što se svaki međunukleozidni veznik od modificiranog oligonukleotida bira između fosforotioatnog međunukleozidnog veznika i fosfodiesterskog međunukleozidnog veznika.
14. Modificirani oligonukleotid, naznačen time, što se sastoji od 18 do 20 povezanih nukleozida koji sadrže nukleobazni slijed SEQ ID NO: 1, pri čemu svaki od 18 nukleozida od modificiranog oligonukleotida sadrži ostatak šećera modificiran skupinom 2'-O-(N-metil acetamid), i time, što se svaki međunukleozidni veznik od modificiranog oligonukleotida bira između fosforotioatnog međunukleozidnog veznika i fosfodiesterskog međunukleozidnog veznika.
15. Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 12, ili modificirani oligonukleotid prema patentnom zahtjevu 13 ili zahtjevu 14, naznačen time, što modificirani oligonukleotid je natrijeva sol ili kalijeva sol.
16. Farmaceutski pripravak, naznačen time, što sadrži oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 12 ili 15, ili modificirani oligonukleotid prema bilo kojem od patentnih zahtjeva 13 do 15, te najmanje jedan farmaceutski prihvatljiv nosač ili razrjeđivač.
17. Farmaceutski pripravak prema patentnom zahtjevu 16, naznačen time, što pripravak sadrži farmaceutski prihvatljiv razrjeđivač, i farmaceutski prihvatljiv razrjeđivač je fosfatna puferirana slana otopina (PBS), opcionalno pritom se farmaceutski pripravak sastoji od spoja i PBS.
18. Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 12 ili 15, modificirani oligonukleotid prema bilo kojem od patentnih zahtjeva 13 do 15, ili farmaceutski pripravak prema patentnom zahtjevu 16 ili 17, naznačen time, što je za uporabu u postupku liječenja pacijenta od spinalne muskularne atrofije.
HRP20221378TT 2016-07-15 2017-07-17 Spojevi i postupci za modulaciju smn2 HRP20221378T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662363195P 2016-07-15 2016-07-15
EP17828625.8A EP3484524B1 (en) 2016-07-15 2017-07-17 Compounds and methods for modulation of smn2
PCT/US2017/042463 WO2018014041A2 (en) 2016-07-15 2017-07-17 Compounds and methods for modulation of smn2

Publications (1)

Publication Number Publication Date
HRP20221378T1 true HRP20221378T1 (hr) 2023-01-06

Family

ID=60952211

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20221378TT HRP20221378T1 (hr) 2016-07-15 2017-07-17 Spojevi i postupci za modulaciju smn2

Country Status (25)

Country Link
US (2) US20190323006A1 (hr)
EP (2) EP3484524B1 (hr)
JP (2) JP7197463B2 (hr)
KR (1) KR102556825B1 (hr)
CN (1) CN109844115B (hr)
AU (1) AU2017297622A1 (hr)
BR (1) BR112019000356A2 (hr)
CA (1) CA3030864A1 (hr)
CL (2) CL2019000115A1 (hr)
CO (1) CO2019001236A2 (hr)
DK (1) DK3484524T3 (hr)
ES (1) ES2935658T3 (hr)
FI (1) FI3484524T3 (hr)
HR (1) HRP20221378T1 (hr)
HU (1) HUE060831T2 (hr)
IL (2) IL264216B2 (hr)
LT (1) LT3484524T (hr)
MX (1) MX2019000619A (hr)
PE (1) PE20190513A1 (hr)
PL (1) PL3484524T3 (hr)
PT (1) PT3484524T (hr)
RS (1) RS63928B1 (hr)
SG (1) SG11201900238UA (hr)
SI (1) SI3484524T1 (hr)
WO (1) WO2018014041A2 (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014169243A2 (en) * 2013-04-12 2014-10-16 The Curators Of The University Of Missouri Smn2 element 1 antisense compositions and methods and uses thereof
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
CA3019145A1 (en) 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
RS62872B1 (sr) 2017-09-27 2022-02-28 Incyte Corp Soli derivata pirrolotriazina korisne kao tam inhibitori
JP2021529765A (ja) 2018-06-29 2021-11-04 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ａｘｌ／ｍｅｒ阻害剤の製剤
JP2022544538A (ja) * 2019-08-15 2022-10-19 バイオジェン・エムエイ・インコーポレイテッド 脊髄性筋萎縮症のための併用療法
JPWO2021054370A1 (hr) * 2019-09-18 2021-03-25
US20220064638A1 (en) 2020-02-28 2022-03-03 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating smn2
FR3128873A1 (fr) 2021-11-10 2023-05-12 Biophytis Phytoecdysones et/ou dérivés de 20-hydroxyecdysone en combinaison avec un principe actif visant à restaurer l’expression SMN pour leur utilisation dans le traitement de l’amyotrophie spinale

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US4751219A (en) 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
JP2828642B2 (ja) 1987-06-24 1998-11-25 ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン ヌクレオシド誘導体
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
BR9106702A (pt) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5948903A (en) 1991-01-11 1999-09-07 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
JP3739785B2 (ja) 1991-11-26 2006-01-25 アイシス ファーマシューティカルズ，インコーポレイティド 修飾されたピリミジンを含有するオリゴマーを使用する増強された三重らせんおよび二重らせんの成形
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US20030119724A1 (en) 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
WO1997020563A1 (en) 1995-11-22 1997-06-12 The Johns-Hopkins University Ligands to enhance cellular uptake of biomolecules
US7875733B2 (en) 2003-09-18 2011-01-25 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation
US6620916B1 (en) 1996-09-26 2003-09-16 Ajinomoto Co., Inc. Modified physiologically active proteins and medicinal compositions containing the same
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
IL135000A0 (en) 1997-09-12 2001-05-20 Exiqon As Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6300319B1 (en) 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
KR100782896B1 (ko) 1999-05-04 2007-12-06 엑시콘 에이/에스 Ｌ-리보-ｌｎａ 유사체
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US6383812B1 (en) 1999-05-28 2002-05-07 Academia Sinica Anti liver disease drug R-YEEE and method of synthesizing branched galactose-terminal glycoproteins
US20080281041A1 (en) 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
US8541548B2 (en) 1999-06-07 2013-09-24 Arrowhead Madison Inc. Compounds and methods for reversible modification of biologically active molecules
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
AU2002217980A1 (en) 2000-12-01 2002-06-11 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US20030175906A1 (en) 2001-07-03 2003-09-18 Muthiah Manoharan Nuclease resistant chimeric oligonucleotides
US20030158403A1 (en) 2001-07-03 2003-08-21 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US20100240730A1 (en) 2002-02-20 2010-09-23 Merck Sharp And Dohme Corp. RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)
WO2004024757A2 (en) 2002-09-11 2004-03-25 Santaris Pharma A/S Modified pna molecules
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004044139A2 (en) 2002-11-05 2004-05-27 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
JPWO2004101619A1 (ja) 2003-05-15 2006-10-26 塩野義製薬株式会社 機能的糖ペプチドの合理的設計および合成
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
ES2382807T3 (es) 2003-08-28 2012-06-13 Takeshi Imanishi Nuevos ácidos nucleicos artificiales del tipo de enlace N-O con reticulación
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
WO2006031461A2 (en) 2004-09-09 2006-03-23 Isis Pharmaceuticals, Inc. Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
US20060148740A1 (en) 2005-01-05 2006-07-06 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
US20080206869A1 (en) 2005-01-24 2008-08-28 Avaris Ab Nucleic Acid Complex
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
KR20130042043A (ko) 2006-01-27 2013-04-25 아이시스 파마수티컬즈 인코포레이티드 6-변형된 바이시클릭 핵산 유사체
DK2066684T3 (da) 2006-05-11 2012-10-22 Isis Pharmaceuticals Inc 5´-Modificerede bicycliske nukleinsyreanaloge
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
US8658211B2 (en) 2006-08-18 2014-02-25 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
CN102614528B (zh) 2006-08-18 2014-02-26 箭头研究公司 用于体内递送多核苷酸的多缀合物
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
EP2606911A1 (en) 2007-02-16 2013-06-26 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
AU2008242583B2 (en) 2007-04-23 2013-10-10 Alnylam Pharmaceuticals, Inc. Glycoconjugates of RNA interference agents
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2009006478A2 (en) 2007-07-05 2009-01-08 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
EP2188298B1 (en) 2007-08-15 2013-09-18 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
AU2008333811B2 (en) 2007-12-04 2014-05-01 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
CA2713379A1 (en) 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Optimized methods for delivery of dsrna targeting the pcsk9 gene
EP2265627A2 (en) 2008-02-07 2010-12-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2009120878A2 (en) 2008-03-26 2009-10-01 Alnylam Pharmaceuticals, Inc. Non-natural ribonucleotides, and methods of use thereof
EP2274425A2 (en) 2008-04-11 2011-01-19 Alnylam Pharmaceuticals Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
HUE037082T2 (hu) 2008-11-10 2018-08-28 Arbutus Biopharma Corp Új lipidek és készítmények terápiás hatóanyagok szállítására
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
JP5769701B2 (ja) 2009-05-05 2015-08-26 テクミラ ファーマシューティカルズ コーポレイションＴｅｋｍｉｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 脂質組成物
DK2440183T3 (en) 2009-06-10 2018-10-01 Arbutus Biopharma Corp Improved lipid formulation
EA201270019A1 (ru) 2009-06-15 2012-06-29 Элнилэм Фармасьютикалз, Инк. Двуцепочечная рнк, включенная в липидный состав и мишенью которой является ген pcsk9
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
WO2011038356A2 (en) 2009-09-25 2011-03-31 Johns Hopkins University Novel liver-targeting agents and their synthesis
TWI388338B (zh) 2009-10-26 2013-03-11 Iner Aec Executive Yuan 對聚合醣鏈進行放射標誌以作為肝受體造影劑之方法
TWI391144B (zh) 2009-10-26 2013-04-01 Iner Aec Executive Yuan 一種定量肝殘餘功能的檢驗方法與其新穎肝受體造影檢驗藥劑
WO2011072290A2 (en) 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
NZ601737A (en) 2010-02-24 2013-06-28 Arrowhead Res Corp Compositions for targeted delivery of sirna
US20130109817A1 (en) 2010-03-26 2013-05-02 Mersana Therapeutics, Inc. Modified Polymers for Delivery of Polynucleotides, Method of Manufacture, and Methods of Use Thereof
WO2011120053A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
WO2011133876A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US9518259B2 (en) * 2010-06-15 2016-12-13 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating interaction between proteins and target nucleic acids
WO2011163121A1 (en) 2010-06-21 2011-12-29 Alnylam Pharmaceuticals, Inc. Multifunctional copolymers for nucleic acid delivery
WO2012012467A2 (en) * 2010-07-19 2012-01-26 Isis Pharmaceuticals, Inc. Modulation of nuclear-retained rna
US9290760B2 (en) 2010-09-15 2016-03-22 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
WO2012068187A1 (en) 2010-11-19 2012-05-24 Merck Sharp & Dohme Corp. Poly(amide) polymers for the delivery of oligonucleotides
EP3192800A1 (en) 2010-12-17 2017-07-19 Arrowhead Pharmaceuticals, Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
CA2976966C (en) 2010-12-29 2021-11-09 F. Hoffmann-La Roche Ag Small molecule conjugates for intracellular delivery of nucleic acids
KR102540778B1 (ko) 2011-06-21 2023-06-07 알닐람 파마슈티칼스 인코포레이티드 아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
KR20140051357A (ko) 2011-08-26 2014-04-30 애로우헤드 리서치 코오포레이션 Ｉｎ Ｖｉｖｏ 핵산 전달용 폴리(비닐 에스테르) 고분자
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
KR102263352B1 (ko) 2011-11-18 2021-06-11 알닐람 파마슈티칼스 인코포레이티드 트랜스티레틴（ＴＴＲ） 관련 질병을 치료하기 위한 ＲＮＡｉ 제제, 조성 및 그의 사용방법
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
TWI595885B (zh) 2012-05-02 2017-08-21 喜納製藥公司 包含四ｇａｌｎａｃ之新穎結合物及傳送寡核苷酸之方法
US9926559B2 (en) * 2013-01-09 2018-03-27 Biogen Ma Inc. Compositions and methods for modulation of SMN2 splicing in a subject
AU2014259759B2 (en) 2013-05-01 2020-06-18 Ionis Pharmaceuticals, Inc. Compositions and methods
JP2016534035A (ja) * 2013-10-04 2016-11-04 ラナ セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症を治療するための組成物及び方法
WO2015106128A2 (en) 2014-01-09 2015-07-16 Alnylam Pharmaceuticals, Inc. MODIFIED RNAi AGENTS
EP4162940A1 (en) * 2014-04-17 2023-04-12 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing in a subject

Also Published As

Publication number Publication date
CL2019000115A1 (es) 2019-06-21
JP7197463B2 (ja) 2022-12-27
EP3484524B1 (en) 2022-11-09
WO2018014041A3 (en) 2019-04-18
WO2018014041A2 (en) 2018-01-18
AU2017297622A1 (en) 2019-03-07
IL264216B2 (en) 2024-04-01
PL3484524T3 (pl) 2023-03-20
IL308256A (en) 2024-01-01
IL264216A (en) 2019-02-28
US20220073914A1 (en) 2022-03-10
BR112019000356A2 (pt) 2019-04-16
EP3484524A2 (en) 2019-05-22
CA3030864A1 (en) 2018-01-18
US20190323006A1 (en) 2019-10-24
KR102556825B1 (ko) 2023-07-17
JP2023027285A (ja) 2023-03-01
CO2019001236A2 (es) 2019-02-19
CN109844115B (zh) 2023-06-30
SG11201900238UA (en) 2019-02-27
PT3484524T (pt) 2023-02-15
EP4206213A1 (en) 2023-07-05
LT3484524T (lt) 2022-12-27
KR20190027907A (ko) 2019-03-15
CL2019003820A1 (es) 2020-07-10
ES2935658T3 (es) 2023-03-09
EP3484524A4 (en) 2020-05-20
JP2019525918A (ja) 2019-09-12
FI3484524T3 (fi) 2023-01-13
MX2019000619A (es) 2019-08-01
HUE060831T2 (hu) 2023-04-28
SI3484524T1 (sl) 2023-01-31
RS63928B1 (sr) 2023-02-28
IL264216B1 (en) 2023-12-01
PE20190513A1 (es) 2019-04-10
CN109844115A (zh) 2019-06-04
DK3484524T3 (da) 2022-12-12

Similar Documents

Publication Publication Date Title
HRP20221378T1 (hr) Spojevi i postupci za modulaciju smn2
JP2017536366A5 (hr)
IL261901A (en) Compositions and methods for modulating apolipoprotein expression
JP2021074021A5 (hr)
HRP20171980T1 (hr) Postupak djelotvornog preskakanja egzona (44) kod duchenneove mišićne distrofije i odgovarajuće sredstvo
JP2017536119A5 (hr)
HRP20211051T1 (hr) Pripravci namijenjeni moduliranju eksprimiranja tau
EP3485015A1 (en) Compounds and methods for modulation of dystrophin transcript
HRP20160336T1 (hr) Protusmjerna nukleinska kiselina
JP2020022483A5 (hr)
IL300119A (en) Oligonucleotides to induce paternal UBE3A expression
RU2017139121A (ru) Композиции для модулирования экспрессии c9orf72
SI2379084T1 (en) Modulation of factor expression 11
HRP20160078T1 (hr) METODE I SREDSTVA ZA UČINKOVITO PRESKAKANJE EKSONA 45 U pre-mRNA DUCHENNE MIŠIĆNE DISTROFIJE
JP2017521045A5 (hr)
JP2019525918A5 (hr)
FI2906696T4 (fi) Menetelmiä c9orf72:n ilmentymisen moduloimiseksi
CL2018001212A1 (es) Composiciones de oligonucleótidos y métodos para realizarlas (divisional de sol. n°2749-16)
RU2016146819A (ru) Композиции и способы модулирования экспрессии рецептора гормона роста
JP2012513953A (ja) 付加環化を用いたモノマーおよびオリゴヌクレオチドの化学修飾
HRP20211293T1 (hr) Pripravci za potporu pri svakodnevnim aktivnostima
JP2019088329A5 (hr)
RU2010144531A (ru) Модифицированная липидами двухцепочечная рнк, обладающая мощным эффектом рнк-интерференции
AU2017229778A1 (en) Methods and compositions for inhibiting PMP22 expression
AU2017297624B2 (en) Compounds and methods for modulation of transcript processing